Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-520, KSP inhibitor · 4 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| ARRY-520 (Schedule 1) + bortezomib + G-CSF | EXPERIMENTAL | - |
| ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF | EXPERIMENTAL | - |
| ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF | EXPERIMENTAL | - |
| ARRY-520 | EXPERIMENTAL | - |
| ARRY-520 + G-CSF support | EXPERIMENTAL | - |
| ARRY-520 + dexamethasone + G-CSF support | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-520, KSP(Eg5) inhibitor; intravenous | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule. |
| Bortezomib, proteasome inhibitor; intravenous or subcutaneous | DRUG | Part 1: standard of care; Part 2: standard of care determined in Part 1. |
| Dexamethasone, steroid; oral | DRUG | Part 1: standard of care; Part 2: standard of care determined in Part 1. |
| Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous | DRUG | Part 1: standard of care; Part 2: standard of care. |
Key Inclusion Criteria (Part 1 and Part 2): * Confirmed relapsed or refractory MM (measurable disease) or PCL. * Prior treatment regimens for Part 1: Patients should have received at least 2 prior treatment regimens. Prior treatment must have included at least one full cycle of a proteasome inhibit...
ARRY-520 is an investigational small molecule being studied for the treatment of multiple myeloma, advanced solid tumors, plasma cell leukemia, and advanced MDS. It is being developed by Pfizer, Inc. (NYSE: PFE) and is currently in Phase 1 clinical development for these oncology indications.
ARRY-520 targets the kinesin spindle protein (KSP), a motor protein essential for cell division. By inhibiting KSP, ARRY-520 is designed to disrupt mitosis in cancer cells. This mechanism is being evaluated in Phase 1 trials for multiple myeloma and other advanced cancers.
Pfizer, Inc. (NYSE: PFE) is developing ARRY-520. The drug is an investigational small molecule currently in Phase 1 clinical trials for oncology indications including multiple myeloma and advanced solid tumors.
ARRY-520 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Multiple Phase 1 trials have been completed, studying the drug in patients with advanced solid tumors, advanced myeloid leukemia, and multiple myeloma.
ARRY-520 has been studied in several completed Phase 1 trials, including NCT00462358 in advanced solid tumors, NCT00637052 in advanced MDS and acute myeloid leukemia, NCT00821249 in relapsed or refractory multiple myeloma, and NCT01248923 combining ARRY-520 with bortezomib and dexamethasone in multiple myeloma.
ARRY-520 is also known as filanesib. It is a kinesin spindle protein inhibitor being developed by Pfizer for multiple myeloma and other cancers. The drug has been evaluated in Phase 1 clinical trials under both names.